Cargando…
Dual activity inhibition of threonine aspartase 1 by a single bisphosphate ligand
Therapy resistance remains a challenge for the clinics. Here, dual-active chemicals that simultaneously inhibit independent functions in disease-relevant proteins are desired though highly challenging. As a model, we here addressed the unique protease threonine aspartase 1, involved in various cance...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709806/ https://www.ncbi.nlm.nih.gov/pubmed/36545626 http://dx.doi.org/10.1039/d2ra06019a |
_version_ | 1784841237394620416 |
---|---|
author | Höing, Alexander Struth, Robin Beuck, Christine Rafieiolhosseini, Neda Hoffmann, Daniel Stauber, Roland H. Bayer, Peter Niemeyer, Jochen Knauer, Shirley K. |
author_facet | Höing, Alexander Struth, Robin Beuck, Christine Rafieiolhosseini, Neda Hoffmann, Daniel Stauber, Roland H. Bayer, Peter Niemeyer, Jochen Knauer, Shirley K. |
author_sort | Höing, Alexander |
collection | PubMed |
description | Therapy resistance remains a challenge for the clinics. Here, dual-active chemicals that simultaneously inhibit independent functions in disease-relevant proteins are desired though highly challenging. As a model, we here addressed the unique protease threonine aspartase 1, involved in various cancers. We hypothesized that targeting basic residues in its bipartite nuclear localization signal (NLS) by precise bisphosphate ligands inhibits additional steps required for protease activity. We report the bisphosphate anionic bivalent inhibitor 11d, selectively binding to the basic NLS cluster ((220)KKRR(223)) with high affinity (K(D) = 300 nM), thereby disrupting its interaction and function with Importin α (IC(50) = 6 μM). Cell-free assays revealed that 11d additionally affected the protease's catalytic substrate trans-cleavage activity. Importantly, functional assays comprehensively demonstrated that 11d inhibited threonine aspartase 1 also in living tumor cells. We demonstrate for the first time that intracellular interference with independent key functions in a disease-relevant protein by an inhibitor binding to a single site is possible. |
format | Online Article Text |
id | pubmed-9709806 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Royal Society of Chemistry |
record_format | MEDLINE/PubMed |
spelling | pubmed-97098062022-12-20 Dual activity inhibition of threonine aspartase 1 by a single bisphosphate ligand Höing, Alexander Struth, Robin Beuck, Christine Rafieiolhosseini, Neda Hoffmann, Daniel Stauber, Roland H. Bayer, Peter Niemeyer, Jochen Knauer, Shirley K. RSC Adv Chemistry Therapy resistance remains a challenge for the clinics. Here, dual-active chemicals that simultaneously inhibit independent functions in disease-relevant proteins are desired though highly challenging. As a model, we here addressed the unique protease threonine aspartase 1, involved in various cancers. We hypothesized that targeting basic residues in its bipartite nuclear localization signal (NLS) by precise bisphosphate ligands inhibits additional steps required for protease activity. We report the bisphosphate anionic bivalent inhibitor 11d, selectively binding to the basic NLS cluster ((220)KKRR(223)) with high affinity (K(D) = 300 nM), thereby disrupting its interaction and function with Importin α (IC(50) = 6 μM). Cell-free assays revealed that 11d additionally affected the protease's catalytic substrate trans-cleavage activity. Importantly, functional assays comprehensively demonstrated that 11d inhibited threonine aspartase 1 also in living tumor cells. We demonstrate for the first time that intracellular interference with independent key functions in a disease-relevant protein by an inhibitor binding to a single site is possible. The Royal Society of Chemistry 2022-11-30 /pmc/articles/PMC9709806/ /pubmed/36545626 http://dx.doi.org/10.1039/d2ra06019a Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/ |
spellingShingle | Chemistry Höing, Alexander Struth, Robin Beuck, Christine Rafieiolhosseini, Neda Hoffmann, Daniel Stauber, Roland H. Bayer, Peter Niemeyer, Jochen Knauer, Shirley K. Dual activity inhibition of threonine aspartase 1 by a single bisphosphate ligand |
title | Dual activity inhibition of threonine aspartase 1 by a single bisphosphate ligand |
title_full | Dual activity inhibition of threonine aspartase 1 by a single bisphosphate ligand |
title_fullStr | Dual activity inhibition of threonine aspartase 1 by a single bisphosphate ligand |
title_full_unstemmed | Dual activity inhibition of threonine aspartase 1 by a single bisphosphate ligand |
title_short | Dual activity inhibition of threonine aspartase 1 by a single bisphosphate ligand |
title_sort | dual activity inhibition of threonine aspartase 1 by a single bisphosphate ligand |
topic | Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709806/ https://www.ncbi.nlm.nih.gov/pubmed/36545626 http://dx.doi.org/10.1039/d2ra06019a |
work_keys_str_mv | AT hoingalexander dualactivityinhibitionofthreonineaspartase1byasinglebisphosphateligand AT struthrobin dualactivityinhibitionofthreonineaspartase1byasinglebisphosphateligand AT beuckchristine dualactivityinhibitionofthreonineaspartase1byasinglebisphosphateligand AT rafieiolhosseinineda dualactivityinhibitionofthreonineaspartase1byasinglebisphosphateligand AT hoffmanndaniel dualactivityinhibitionofthreonineaspartase1byasinglebisphosphateligand AT stauberrolandh dualactivityinhibitionofthreonineaspartase1byasinglebisphosphateligand AT bayerpeter dualactivityinhibitionofthreonineaspartase1byasinglebisphosphateligand AT niemeyerjochen dualactivityinhibitionofthreonineaspartase1byasinglebisphosphateligand AT knauershirleyk dualactivityinhibitionofthreonineaspartase1byasinglebisphosphateligand |